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Do we have to change our anti-cancer 
strategy in case of cardiac toxicity?
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• New anticancer therapies have led to long life 
expectancy for many patients 
• Treatment related  co morbidities have 
become an issue for cancer survivors
Anticancer therapy: cardiac toxicity
• Cardiac toxicity vary from mild ECG changes 
to serious arrhythmias, myocarditis, 
pericarditis, MI  & heart failure
Cardiac disease does matter in early stage 
breast cancer
Patients (age at least 50) with early stage breast cancer are 
4x more likely to die of non-cancer conditions (up to 45 % 
are cardiac in nature) 
Hanrahan, et al. JCO 25: 4952-4960, 2007
• Reversible (at least partially)? Monitoring
• Cumulative dose-dependent? Adapt regimen
Anticancer therapy and cardiac toxicity:
the drug
• Major risk factors well known? Patient 
selection
• Childhood tumors:
- curative treatment, not adjuvant
- low incidence 
Anticancer therapy and cardiotoxicity : 
specific oncological situations
- anthracyclines frequently used
• Very long life expectancy
• Risk factors? How to adapt treatment? 
Adjuvant treatment of common cancers, such 
as breast cancer
Avoid or reduce exposure to cardiotoxic drugs 
Anticancer therapy and cardiotoxicity : 
specific oncological situations
such as anthracyclines: 
Anthracycline free adjuvant regimens or  
sequential therapy with taxanes, reducing 
cumulative toxicity 
Challenges: 
- Long term follow -up if late occurrence of 
cardiotoxicity
- Outcome in the real world setting??? (highly 
Anticancer therapy and cardiotoxicity : 
specific oncological situations
selected, exclusion of patients with high risk of 
cardiotoxicity, younger patients in clinical trials )
Patient selection is a key factor (oncological and 
cardiotoxicity risk?)
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• Small molecules can 
block the RTK signal 
at the source
Adjuvant Trastuzumab Trials





































Time to First Distant Recurrence
AC, cyclophosphamide + doxorubicin; P, paclitaxel; T, trastuzumab.
Adapted from Romond EH, et al. New Engl J Med. 2005;353(16):1673-1684.
HR = 0.47, P < .0001






















Suter et al. J Clin Oncol 25: 3859-65, 2007
• Use of anthracyclines?
• Use of trastuzumab ?
Anticancer therapy: HER2 positive breast 
cancer
• Combined treatment or sequential treatment?
Trastuzumab : Changes in left
ventricular ejection fraction
Ewer, et al. JCO 23: 7820-6, 2007
Trastuzumab : cardiac monitoring
Martin M et al., The Oncologist 14: 1-11, 2009
Adjuvant trastuzumab
cardiotoxicity
Tarantini et al. Ann Oncol 23: 3058-63, 2012
BCIRG 006: Risk of relapse
33% 39%



















BCIRG 006 : cardiotoxicity
CHF
NYHA grade III IV
4 20 4
Trastuzumab used without prior anthracycline is largely 
more safe
Benefit : difference between AC-TH and TCH isn’t 
statistically significant
Why not using Herceptin as first agent?
Cardiac toxicity: trastuzumab
Bird B R H , and Swain S M Clin Cancer Res 2008;14:1 4-24
NSABP B -31
Cardiac Risk Score
Factors associated with risk of developing a 
cardiac event:
 Use of hypertensive medications
 Age >49
 Baseline LVEF <54
Risk Score = 100 x 7.4(0.03 x Age)  – (0.10 + baseline LVEF) + (0.68 x  C)( .   li  )  ( .   C)
4.82
C = HTN medication status: none = 0; yes = 1




62 yo woman on antihypertensive medication
Baseline LVEF = 60%






























( 0 . 0 2 4 , 5 0 )
( 0 . 0 4 , 6 2 )
Cardiac Risk Score = 82
3-year predicted incidence of 
symptomatic heart 
failure/cardiac death ≅ 10%
Future Directions
PREVENTION ?
• Pre-emptive use of ACE inhibitors or beta-blockers in 
may prevent cardiotoxicity
EARLY DETECTION
• Cardiac biomarkers may help identify high risk 
patients 
CLOSE  COLLABORATION !!!
